Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease

BACKGROUND: New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side effects, particularly for patients requiring anticoagulation or thrombolysis for cardiovascular conditions. Given that most patients with AD are older and likely to have cardiovascular risk factors, there is urgent need for additional guidance for clinicians about potential risks and benefits associated with AAT for patients with cardiovascular comorbidities, best practices for management of these patients, and special considerations with respect to emergency evaluation and treatment of patients on AAT who develop acute neurological symptoms. METHODS: The American Heart Association convened 75 multidisciplinary experts for the Amyloid-Related Imaging Abnormalities Summit: Cardiovascular and Stroke Considerations for β-Amyloid Immunotherapy in AD in July 2025. These experts were divided into 8 work groups to evaluate the current evidence related to AAT usage in patients with cardiovascular risk factors and conditions and develop consensus-based guidance for clinicians. RESULTS: This statement outlines the outcomes of the Summit, including considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders. These considerations are intended to improve identification of patients as appropriate candidates for AAT, management of patients with co-occurring AD and cardiovascular conditions, and their emergency evaluation and treatment. The statement also includes guidance for shared decision-making, implementation of system changes for improving dementia care, and recommendations for future research and data collection to add to the body of evidence for treating patients with concomitant AD and cardiovascular conditions. CONCLUSIONS: Building on lessons learned from the establishment of stroke systems of care, the consensus-based considerations outlined in this document can serve as a foundation for AD systems of care aimed at ensuring optimal use of these ground-breaking therapies.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-08-20
DOI
https://doi.org/10.1161/jaha.125.048108
Primary Topic
Intracerebral and Subarachnoid Hemorrhage Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease

Richard B. Lipton, Heather M. Snyder, Costantino Iadecola, Sudha S. Seshadri et al.
Journal of the American Heart Association
Intracerebral and Subarachnoid Hemorrhage Research
article

Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease

Richard B. Lipton, Heather M. Snyder, Costantino Iadecola, Sudha S. Seshadri, Sherry Chou, Janice Y. Chyou, Mitchell S.V. Elkind, Caitlin Le, Sachin J. Shah, Irina Skylar-Scott, Lauren Massimo, Alejandro A. Rabinstein, Matthew W. Schelke, Tara C. Carlisle, Richard G. Wunderink, Alessandro Biffi, Makoto Ishii, Kristine S. Yaffe, Mary Ann Bauman, Arindam Rano Chatterjee, Steven Mark Greenberg, David C. Weisman, Kori Sauser Zachrison, Stephen R. Saklad, Ronald M. Lazar, Hanlin Li, Deborah A. Levine, Stephanie M. Mohl, Christian T. Ruff, Larry B Goldstein, Louise McCullough, Petrice M Cogswell, Karen Orjuela, Magdy Selim, Marion Buckwalter, Brian Stamm, Colin Derdeyn, Kenrick Cato, Alexander Chaitoff, José G. Merino, Cameron Gettel, William J. Hicks II, Sharon J. Sha, Vijay K. Ramanan, James L. Bernat, Maggie Tubiello, Salvador Cruz‐Flores, Ambar Kulshrestha, Gloria Chiang, Steve Messe, Amar Dhand, Thierry Bussiere, Robert Adams, Alireza Atri, Christine Lam, Maria C. Carrillo, Jeffrey Saver, Manu S. Goyal, Tracy Madsen, Marc Agronin, Suzanne Bakken, Gil D. Rabinovici, Lawren VandeVrede, Joshua Grill, Helen Lavretsky, Sonja Blum, Kevin Sheth, Michael Guo, David A. Evans
article en

Abstract

BACKGROUND: New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side effects, particularly for patients requiring anticoagulation or thrombolysis for cardiovascular conditions. Given that most patients with AD are older and likely to have cardiovascular risk factors, there is urgent need for additional guidance for clinicians about potential risks and benefits associated with AAT for patients with cardiovascular comorbidities, best practices for management of these patients, and special considerations with respect to emergency evaluation and treatment of patients on AAT who develop acute neurological symptoms. METHODS: The American Heart Association convened 75 multidisciplinary experts for the Amyloid-Related Imaging Abnormalities Summit: Cardiovascular and Stroke Considerations for β-Amyloid Immunotherapy in AD in July 2025. These experts were divided into 8 work groups to evaluate the current evidence related to AAT usage in patients with cardiovascular risk factors and conditions and develop consensus-based guidance for clinicians. RESULTS: This statement outlines the outcomes of the Summit, including considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders. These considerations are intended to improve identification of patients as appropriate candidates for AAT, management of patients with co-occurring AD and cardiovascular conditions, and their emergency evaluation and treatment. The statement also includes guidance for shared decision-making, implementation of system changes for improving dementia care, and recommendations for future research and data collection to add to the body of evidence for treating patients with concomitant AD and cardiovascular conditions. CONCLUSIONS: Building on lessons learned from the establishment of stroke systems of care, the consensus-based considerations outlined in this document can serve as a foundation for AD systems of care aimed at ensuring optimal use of these ground-breaking therapies.

Journal of the American Heart Association
OhioHealth (US), Alzheimer's Association (US), American Heart Association (US), Albert Einstein College of Medicine (US), The University of Texas at San Antonio Health Science Center (US), University of California, San Francisco (US), Cornell University (US), WinnMed (US), California University of Pennsylvania (US), Massachusetts General Hospital (US), Michigan Medicine (US), Weill Cornell Medicine (US), The University of Texas at San Antonio (US), University of Pennsylvania (US)
Peace, Justice and strong institutions
Openalex Percentile: Top 10%
Intracerebral and Subarachnoid Hemorrhage Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.